Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Janssen Discloses 2013 Payments of 8.3 Billion Yen to Healthcare Professionals
September 10, 2014
- Otsuka to Launch Deltyba on September 26; Launch Delayed in Anticipation of Revised TB Treatment Guidelines
September 10, 2014
- Medical & Biological Lab Seeking Partner for Dengue Fever Drug Development
September 9, 2014
- Announcement: Sales Excellence Japan 2014 to Be Held on October 14, 15
September 9, 2014
- Ethical Drug Sales Down 3.0% in July: Crecon Report
September 9, 2014
- Ono, Bristol-Myers Sue Merck over Anti-PD-1 Antibody Patent
September 9, 2014
- Chugai Launches ALK Inhibitor Alecensa
September 9, 2014
- Pfizer Japan, Astellas to Terminate Copromotion Deal for Caduet in March Next Year
September 9, 2014
- MSD Sales Structure Now Tailored to Local Healthcare Needs: Pres.
September 8, 2014
- All Eyes Glued to Japan Realignment after Mylan’s Buyout of Abbott’s Established Product Biz
September 8, 2014
- Meiji Seika Pharma, Takeda to Copromote Insomnia Treatment Rozerem from October
September 8, 2014
- Bayer Yakuhin Files Eylea for Macular Edema Secondary to Branch Retinal Vein Occlusion
September 8, 2014
- Takeda Files Leuplin 6-Month Depot Formulation in Japan
September 8, 2014
- MSD’s Januvia Logs 1st Sales Decline in Japan on Re-Pricing
September 5, 2014
- Januvia Retains Its No. 1 Spot in the GP Market in July: Anterio’s “Mind Share” Ranking
September 5, 2014
- Takeda Transfers All Shares of Its Subsidiary Nippon-Rinshosha to Medical Tribune
September 5, 2014
- Sanofi Launches Prostate Cancer Agent Jevtana
September 5, 2014
- Kaketsuken Completes New Manufacturing Plant for Increasing Production Capacity of Hepatitis B Vaccine
September 5, 2014
- US Court Backs Jury Verdict in Actos Suit, Orders Takeda to Pay US$6 Billion in Punitive Damages
September 5, 2014
- TMRC to Collaborate with Children’s Hospital Los Angeles to Develop Treatment for Chemotherapy-Induced Neutropenia
September 4, 2014
ページ
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…